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Abstract 15 
Suboptimal adherence to antiretroviral (ARV) therapy can lead to insufficient drug exposure 16 
leading to viral rebound and increased likelihood of resistance. This has driven the 17 
development of long-acting injectable (LAI) formulations which may mitigate some of these 18 
problems. Maraviroc (MVC) is an orally dosed CCR5 antagonist approved for use in patients 19 
infected with CCR5-trophic HIV-1. MVC prevents viral entry into host cells, is readily 20 
distributed to biologically relevant tissues and has an alternative resistance profile compared 21 
to more commonly used therapies. This makes a MVC LAI formulation particularly appealing 22 
for implementation in Pre-Exposure Prophylaxis (PrEP). A 70 wt.% MVC-loaded 23 
nanodispersion stabilised with polyvinyl alcohol (PVA) and sodium 1,4-bis(2-ethylhexoxy)-1,4-24 
dioxobutane-2-sulfonate (AOT) was prepared using emulsion-templated freeze-drying. In vitro 25 
release rate studies revealed over a 22% decrease in MVC release rate constant across a 26 
size selective membrane compared with an aqueous solution of MVC (<5% DMSO). 27 
Pharmacokinetic studies in rats were subsequently carried out following intramuscular 28 
injection of either the nanodispersion or an aqueous MVC preparation (<5% DMSO). Results 29 
demonstrated over a 3.4-fold increase in AUC0-∞ (1959.71 vs 567.17 ng.h ml), over a 2.6-fold 30 
increase in MVCs terminal half-life (t½) (140.69 vs 53.23 h) and MVC concentrations present 31 
up to 10-days. These data support development of a MVC LAI formulation with potential 32 
application in HIV therapy or prevention.             33 
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Introduction  38 
The introduction of antiretroviral therapy (ART) has significantly reduced HIV-associated 39 
morbidity and mortality and has transformed HIV infection into a manageable chronic 40 
condition. Currently, there are over 20 antiretrovirals (ARVs) from 6 drug classes and multiple 41 
effective first-line regimens for HIV-1 treatment [1]. Despite these advances, strict adherence 42 
to daily oral ART remains essential in maintaining viral suppression, preventing the emergence 43 
of resistance to therapy and reducing the risk of HIV transmission [2,3]. Additionally, 44 
insufficient drug concentrations at anatomically important locations has been shown to lead to 45 
persistent viral replication and maintenance of the disease [4,5].   Pre-exposure prophylaxis 46 
(PrEP) using ART has been shown to be effective in the prevention of HIV acquisition in 47 
individuals identified as being at risk of infection [6]. Currently, the only drugs used for HIV-1 48 
PrEP are once-daily orally administered tenofovir, tenofovir/emtricitabine or 49 
tenofovir/lamivudine [7,8]. Studies have shown a clear dose-response relationship between 50 
protection and adherence to therapy [9]. The challenges presented by daily oral dosing and 51 
the requirement for life-long maintenance of such dosing has driven interest in the 52 
development of more convenient dosing schedules for both HIV treatment and PrEP.        53 
 54 
A number of strategies have been used to deliver long-acting therapeutics including implants 55 
and injectables. Long-acting reversible contraception methods such as the levonorgestrel 56 
subdermal hormone implant provides a reversible and highly effective means of long-term 57 
pregnancy prevention. The implant consists of two sealed silastic tubes, each containing 58 
75 mg levonorgestrel which provides up to 5 years of effective contraceptive protection 59 
[10,11]. Subdermal implants have, until recently, received little attention for the delivery of 60 
ARVs.  However, implants containing the prodrug tenofovir alafenamide (TAF) are currently 61 
being developed towards PrEP applications. A novel subdermal TAF implant, consisting of a 62 
TAF core inside a silicone scaffold was pharmacologically assessed in beagle dogs. The 63 
implant was shown to maintain a low systemic plasma exposure of both TAF and tenofovir 64 
(TFV) for 40 days. High concentrations of the pharmacologically active metabolite, TFV 65 
diphosphate (TFV-DP), was observed in peripheral blood mononuclear cells (PBMCs) at 66 
levels over 30-fold greater than required for HIV PrEP in humans [12]. More recently, a 67 
biodegradable TAF containing subcutaneous implant for HIV PrEP was assessed in New 68 
Zealand White rabbits. The pharmacokinetic data revealed that plasma TAF concentrations 69 
were detectable up to 70 days following implantation and that plasma TFV and PBMC TFV-70 
DP concentrations were sustained throughout the 3-month study. Additionally, TFV-DP was 71 
detectable in vaginal, cervical and rectal tissues at 49 days, but had declined by day 91 [13].              72 
 73 
 74 
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Another strategy that is attracting interest is the development of long-acting injectables (LAIs), 75 
the concepts for which were initially developed for antipsychotic therapies [14,15] and 76 
contraception [16]. Currently, two solid drug nanoparticle (SDN) ARVs; rilpivirine and 77 
cabotegravir have entered clinical development as LAI formulations both with HIV treatment 78 
and prevention potential [17,18]. This potential was demonstrated in the phase 2b clinical trial; 79 
LATTE-2, involving treatment-naïve HIV-1 infected patients. In the trial, a once daily, three-80 
drug, orally dosed ART (cabotegravir 30 mg; abacavir-lamivudine 600 mg – 300 mg) was 81 
compared to a long-acting intramuscular dose of cabotegravir plus rilpivirine at either a 4-week 82 
(400 mg; 600 mg, respectively) or 8-week dosing interval (600 mg; 900 mg, respectively). 83 
Results from the trial indicated that the long-acting injectable 4-week and 8-week regimens 84 
were well accepted and tolerated by patients and maintained virological suppression at rates 85 
comparable to a daily oral three-drug regimen [19]. Recently, a dolutegravir (DTG) prodrug 86 
preparation was created and encapsulated into poloxamer solid drug nanocrystals to produce 87 
a long-acting parenteral formulation. Pharmacokinetic analysis of DTG nanoparticles and the 88 
DTG-prodrug nanoparticles was carried out over 8 weeks following intramuscular injection in 89 
mice. DTG half-life was increased from 61.9 h to 330.4 h for the prodrug-loaded nanocrystals 90 
and average blood DTG concentrations remained above the PA-IC90 for 8-weeks and tissue 91 
concentrations remained above the PA-IC90 for 4-weeks. It was noted that drug nanocrystals 92 
were observed inside tissue macrophages and stored in the endosomes and 93 
autophagosomes. It is suggested that a secondary depot within the tissue macrophages, 94 
independent of the muscle at the site of injection, developed and influenced DTG exposure  95 
[20]. In addition to providing extended drug exposure, mitigating the need for daily oral dosing 96 
of potentially poorly bioavailable ARVs, LAI preparations have the potential for reducing drug 97 
metabolism, reducing gastrointestinal toxicity, and avoiding some drug-drug interactions [21]. 98 
The mechanisms which underpin drug release from this route of administration are currently 99 
not well understood, but data are beginning to emerge [22–25].       100 
 101 
Maraviroc (MVC) has particular appeal for implementation in PrEP. It is readily absorbed into 102 
cervicovaginal and rectal tissues and is detectable in seminal plasma [26,27]. Recent studies 103 
have highlighted concerns regarding the emergence of drug-resistant HIV strains in patients 104 
who become infected with HIV whilst receiving PrEP [28,29]. MVC is a CCR5 antagonist and 105 
has a unique resistance profile compared to other ARVs.  It is indicated for use in combination 106 
with other ARVs for the treatment of only CCR5-tropic HIV-1 infection in patients 2 years of 107 
age and older weighing ≥10 kg but is not commonly used in front-line therapy, even though 108 
resistance is rare [30,31]. Given MVCs unique resistance profile, it is unlikely that resistance 109 
will develop towards other mainstream front-line future therapy options should a patient 110 
become infected with HIV whilst receiving MVC PrEP.   In addition, HIV-1 infection usually 111 
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occurs through infection with CCR5-tropic virus meaning MVC may be particularly useful in 112 
PrEP.  113 
 114 
The efficacy of orally dosed MVC containing PrEP regimens was previously assessed in the 115 
phase 2, 48-week, clinical trials; HPTN 069 and ACTG A5305. Efficacy was assessed in both 116 
men who have sex with men (MSM) and women who are at risk for HIV infection. Eligible 117 
participants received 1 of 4 MVC containing ARV regimens including; MVC alone (300 mg), 118 
MVC plus emtricitabine (300 mg; 200 mg, respectively), MVC plus tenofovir (300 mg; 300 mg, 119 
respectively) or tenofovir plus emtricitabine (300 mg; 200 mg, respectively) as a control arm. 120 
Among the 406 male participants, five acquired HIV infection (4 participants receiving MVC 121 
only, and 1 participant receiving MVC plus tenofovir). From the five participants who acquired 122 
HIV, 2 had undetectable drug concentrations at every visit, 2 had low concentrations at 123 
seroconversion and 1 participant had variable concentrations. Among the 188 female 124 
participants in the trial, none acquired HIV infection. MVC containing PrEP regimens were 125 
found to be safe and well tolerated compared with tenofovir/emtricitabine regimens in US men 126 
and women [32,33]            127 
 128 
Here, we describe the use of an emulsion-templated freeze-drying (ETFD) technique [34] in 129 
the development of a MVC solid drug nanodispersion to investigate the potential of the 130 
formulation as a LAI. The standard MVC adult oral dose is 300 mg twice-daily, 600 mg twice-131 
daily for patients receiving a CYP3A inducer (in the absence of a potent CYP3A inhibitor) and 132 
150 mg twice-daily for patients receiving a CYP3A inhibitor [35]. In addition to being a CYP3A 133 
substrate, MVC is a P-glycoprotein (P-gp) substrate which reduces effective oral absorption 134 
[36]. Once absorbed, MVC is also a substrate for hepatic OATP1B1, which greatly facilitates 135 
its clearance from the systemic circulation [37]. It is estimated that over 60% of the absorbed 136 
drug is metabolised at first-pass, primarily by CYP3A, resulting in an estimated oral 137 
bioavailability of approximately 33% [38]. The extensive metabolism of MVC following oral 138 
administration and the need for dose adjustment make the development of an alternative 139 
dosing strategy particularly appealing. In this exploratory study we assessed the potential of 140 
a MVC nanodispersion as a LAI for use as PrEP using both in vitro release rate and in vivo 141 
pharmacokinetic approaches.         142 
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Experimental section 143 
Materials 144 
Dimethyl sulfoxide (DMSO), HEPES, bovine serum albumin (BSA), phosphate buffered saline 145 
(PBS), Hanks’ balanced salt solution (HBSS), γ-globulin from bovine blood, dichloromethane, 146 
polyvinyl alcohol (PVA) and sodium 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate 147 
(AOT) were all purchased from Sigma-Aldrich (UK). All other chemicals and reagents were 148 
purchased from Sigma-Aldrich (UK) and used as received, unless stated otherwise. Maraviroc 149 
was kindly gifted by ViiV Healthcare (UK) and [3H]-maraviroc was purchased from Moravek 150 
(US). Liquid scintillation fluid was purchased from Meridian biotechnologies (UK). Rapid 151 
Equilibrium Dialysis (RED) plates and inserts with a 8 kDa MWCO were purchased from 152 
Thermo Fisher Scientific (UK).    153 
 154 
SDN MVC production and characterisation  155 
MVC SDNs were prepared as described elsewhere in this issue [39]. Aqueous stock solutions 156 
of PVA and AOT were prepared at 22.5 mg ml, Maraviroc was prepared at 70 mg ml in 157 
dichloromethane. 70 wt% MVC loaded solid drug nanoparticles (SDN) stabilised with PVA and 158 
AOT (MVCSDNPVA/AOT) was prepared as followed: Solutions were prepared at a 4:1 water:oil 159 
mix, with 90 μl polymer (PVA), 45 μl surfactant (AOT) and 265 μl water added to 100 μl 160 
Maraviroc in DCM. The resulting mixture was emulsified with a Covaris S2x for 30 seconds 161 
with a duty cycle of 20, intensity of 10 and 500 cycles/burst in frequency sweeping mode, after 162 
which samples were immediately cryogenically frozen. Samples were then lyophilised using a 163 
Virtis benchtop K freeze dryers for 48 hours, and then sealed until analysis. Immediately prior 164 
to analysis, samples were dispersed in a volume of water to give 1 mg/ml concentration with 165 
respect to drug concentration. The z-average diameter (nm) of the SDNs was measured using 166 
dynamic light scattering (Malvern Zetasizer Nano ZS) using automatic measurement 167 
optimisation and Malvern Zetasizer software version 7.11 for data analysis. 168 
 169 
Evaluation of MVC release rates using Rapid Equilibrium Dialysis (RED) 170 
The rate of MVCs release from the SDN preparation was assessed across a size selective 171 
(8 kDa MWCO) membrane using RED plates and inserts (Thermo Fisher Scientific). Either 172 
Transport Buffer (TB) consisting of; Hanks balanced salt solution, 25 mM HEPES and 0.1% 173 
Bovine Serum Albumin (BSA), pH 7.4 or Simulated Interstitial Fluid (SIF) consisting of; dH2O, 174 
3.5% BSA and 0.2% γ-globulin, pH 7.4, were spiked with either DMSO dissolved MVC (<5% 175 
DMSO) or MVCSDNPVA/AOT. A total of 1 mg [3H]-MVC (2 µCi mg) was added to the donor 176 
compartments for both preparations in 0.2 ml dH2O with an additional 0.3 ml of either TB or 177 
SIF added to the donor chambers. One-millilitre of either TB or SIF was subsequently added 178 
to the corresponding acceptor chambers. The RED plates were sealed using Parafilm to avoid 179 
6 
 
evaporation and placed on an orbital shaker (Heidolph Rotomax 120; 100 rpm, 6 h, 37oC). 180 
Acceptor contents were subsequently sampled (0.6 ml) at 0.5, 1, 2, 3, 4, 5 and 6 h and 181 
replaced with an equal volume of fresh pre-warmed (37oC) SIF or TB. Collected samples (0.1 182 
ml) were placed into empty 5 ml scintillation vials before mixing with liquid scintillation fluid 183 
(4 ml). Radioactivity was determined as disintegrations per minute (DPM) using a Packard Tri-184 
carb 3100TR liquid scintillation counter. Data were expressed as the amount of [3H]-MVC 185 
released and diffused across the size selective membrane as a first-order release rate 186 
constant calculated over the 6 h incubation.    187 
 188 
In vivo analysis of MVCSDNPVA/AOT  as a LAI   189 
All animal work was conducted in accordance with the Animals (Scientific Procedures) Act 190 
1986 (ASPA) implemented by the UK Home Office. The rodents were housed with 191 
environmental enrichment and a 12 h light/dark cycle at 21oC ±2oC. Free access to food and 192 
water was provided at all times. Following 7-days acclimatisation, adult male Wistar rats (280-193 
330 g) (Charles River, UK) were dosed intramuscularly with 10 mg/Kg MVC at 20 µCi/mg, 194 
after skin disinfection, with either a conventional [3H]-MVC preparation (<5% DMSO) or a [3H]-195 
MVCSDNPVA/AOT nanodispersion into the left hind leg (musculus biceps femoris) using a 25G 196 
needle. Subsequently, blood samples were collected (0.25 ml) post-dosing from the tail vein 197 
until [3H]-MVC activity levels fell below the limits of detection (2 ng/ml). At the terminal 198 
timepoint, the rats were sacrificed using cardiac puncture under terminal anaesthesia 199 
(isoflurane/oxygen), followed by immediate exsanguination of blood from the heart. 200 
Subsequently, an overdose of sodium pentobarbitone (Animalcare, UK) was administered 201 
using the same in situ puncture needle.    202 
 203 
Quantification of radiolabelled plasma 204 
Blood samples were collected in heparinised Eppendorf tubes and centrifuged at 3,000 rpm 205 
for 5 min. The plasma layer was collected and stored at -20oC prior to analysis. Subsequently, 206 
0.1 ml of each plasma sample was transferred into scintillation vials before adding scintillation 207 
fluid (4 ml) (Meridian Biotechnologies, UK) and scintillation counting using a Packard Tri-carb 208 
3100TR.   209 
 210 
Statistical analysis  211 
Statistical analysis was performed using GraphPad Prism v.7 (US). Data normality was 212 
assessed with the Shapiro-Wilk test using StatsDirect v.3 (UK). Data were found to be 213 
normally distributed and unpaired, two-tailed t-tests were applied. For all comparisons, 214 
differences were considered statistically significant at *, P<0.05. Results are expressed as 215 
means and associated standard deviations. The pharmacokinetic parameters; maximum 216 
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concentration (Cmax), the time to Cmax (Tmax), trough concentrations (Cmin) and the average 217 
concentration (Cavg) were derived from the concentration-time profiles. The area under the 218 
curve, (AUC0-4; AUC0-∞) and terminal half-life (t½) were calculated using PKSolver [40].     219 
220 
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Results and discussion 221 
 222 
SDN materials and characterisation  223 
MVCSDNPVA/AOT was prepared using an emulsion-templated freeze-drying method (EFTD) and 224 
was selected as the formulation for this study from a 49 screen matrix of polymer and 225 
surfactants, as previously described [39]. The formulation gave fully water dispersible solid 226 
drug nanoparticles with a hydrodynamic diameter in the region of 750 nm as measured by 227 
DLS. [3H]-MVC was incorporated into the formulation by spiking the initial MVC stock solution 228 
with the radiolabelled MVC. Incorporation of the radiolabelled [3H]-MVC does not affect the 229 
physical properties of the MVCSDNPVA/AOT. 230 
 231 
In vitro MVC release 232 
An understanding of a formulation’s in vitro release rate characteristics can be used to predict 233 
the rate of antiretroviral release from an intramuscular depot. Such information could 234 
potentially be used to predict dosage requirements that provide effective pharmacokinetic 235 
exposure relative to antiretroviral potency [41]. The rate of [3H]-MVC release from the 236 
MVCSDNPVA/AOT was assessed across a size selective membrane (8 kDa MWCO) using two 237 
relevant buffers and compared to an equivalent conventional preparation of [3H]-MVC (<5% 238 
DMSO). The first-order release rate constant results, outlined in Fig. 1, indicate a reduction in 239 
MVC release rate and subsequent diffusion across the size selective membrane when 240 
formulated as MVCSDNPVA/AOT in both TB and SIF. Specifically, MVC release rate constant was 241 
shown to be 22.7% and 10% lower for MVCSDNPVA/AOT compared to the release rate constant 242 
for the conventional preparation in TB and SIF, respectively. Interestingly, the overall rate of 243 
MVC release for both preparations was increased in SIF compared to TB which is possibly 244 
attributed to the higher protein content of the SIF buffer. Given the modified in vitro release 245 
rates, an in vivo assessment of [3H]-MVCs exposure following intramuscular injection was 246 
warranted.            247 
 248 
In vivo LAI MVC study 249 
A rat model was used to investigate the potential of MVCSDNPVA/AOT as a long-acting 250 
formulation. MVC exposure was assessed following a single intramuscular injection of either 251 
the MVCSDNPVA/AOT nanodispersion or a conventional MVC preparation (<5% DMSO). A dose 252 
of 10 mg/Kg [3H]-MVC was injected into the left hind leg of each rat and blood samples were 253 
collected until [3H]-MVC activity levels fell below the limits of detection. The results in Fig. 2. 254 
show both [3H]-MVC exposure over the initial 24 h (insert), encompassing the ‘burst event’ 255 
and exposure for the duration of the procedure, until [3H]-MVC plasma concentrations fell 256 
below the limits of quantification. The pharmacokinetic parameters outlined in Table 1. show 257 
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a comparable Cmax (72.96 vs 71.67 ng ml), an increase in Tmax (time to achieve Cmax after 258 
dosing, 2.0 vs. 1.0 h), increased AUC0-24 (652.66 vs. 244.29 ng.h ml), increased AUC0-∞ 259 
(1959.71 vs. 567.17 ng.h ml) and increased terminal half-life (t½) (140.69 vs. 53.23 h) for the 260 
nanodispersion dosed rats. Following the initial rapid release of MVC, which led to the 261 
pronounced peak in plasma concentrations, the concentrations declined to 5.13% and 11.42% 262 
of the Cmax value within 24 h for the conventional and MVCSDNPVA/AOT preparations, 263 
respectively. After 24 h the [3H]-MVC plasma concentrations remained comparatively stable, 264 
declining steadily so that [3H]-MVC was detectable for 3- and 10-days post-dosing for the 265 
conventional and nanodispersion preparations, respectively. It is interesting to note that 266 
comparable MVC concentrations were observed at 1-week post-dosing (C240) for 267 
MVCSDNPVA/AOT and 1-day post-dosing (C24) for the conventional MVC preparation (2.08 ng ml 268 
vs. 3.67 ng ml). The terminal half-life (t½) for orally dosed MVC is ~17 h compared to an 269 
observed (t½) of 53.23 h and 140.69 h for the intramuscularly dosed conventional MVC 270 
preparation and MVCSDNPVA/AOT, respectively. Relatively low inter-individual variability was also 271 
noted for both treatment groups.   272 
 273 
This exploratory study has identified a MVC nanodispersion with enhanced exposure 274 
compared to a conventional injected preparation. As outlined above, parenteral 275 
nanodispersions would appear to offer a simple and effective way of drug delivery and can 276 
provide unique benefits over current oral dosing strategies. However, the complex 277 
physiochemical properties and molecular mechanisms that allow for and influence protracted 278 
drug release from LAI nanodispersions are currently poorly understood [17]. If 279 
pharmacokinetic variability is driven by the rate of drug release from the injected depot then 280 
there are likely to be a number of depot specific physiological, anatomical and environmental 281 
factors that contribute to drug exposure, the potential significance of each of these has been 282 
reviewed recently [17]. An improved understanding of the mechanisms that permit extended 283 
drug release and protracted systemic drug exposure from LAI drug depots will ultimately help 284 
inform future nanoformulation designs and optimise release characteristics for particular 285 
diseases. Previous mechanistic studies into the tissue response to subcutaneous 286 
norethindrone implants (85% norethindrone, 15% cholesterol) may provide some insight into 287 
the mechanism that underpin drug release and exposure characteristics from LAI depots. In 288 
the study, microscopy was used to assess whether inflammatory responses played a role in 289 
drug absorption from the implants, in rats. It was noted that a dense fibrous biological 290 
compartment was formed around the implanted rods. The cellular tissue surrounding the rods 291 
was mainly composed of lipid laden macrophages which were contained within a fibrous 292 
envelope consisting of blood and lymphatic vessels. Increasing levels of norethindrone was 293 
observed in the formed tissue capsules, between 3 and 10.5 months post implantation. It was 294 
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suggested that the local inflammatory response played a substantial role in the processing of 295 
the implant drug delivery system [42].         296 
 297 
Of particular interest for ARV therapy is the potential role of macrophages in enhancing drug 298 
distribution from the injected depot site. Macrophages have a critical role in HIV transmission, 299 
dissemination and are thought to act as reservoirs of the virus throughout infection [43,44]. 300 
Multimodal molecular imaging in rats has been used to assess the location of a LAI 301 
cabotegravir intramuscular depot and used to monitor volumetric and physiological changes 302 
at the depot site. Early rapid expansion of the cabotegravir depot volume was noted and 303 
associated with increased macrophage accumulation and subclinical oedema in and around 304 
the depot region, which was not identified in the vehicle control. Additionally, cabotegravir 305 
plasma concentrations were related to depot expansion within the first 4-days post 306 
administration [25]. Studies into the local disposition of the antipsychotic drug paliperidone 307 
palmitate, a solid drug particle preparation, identified the development of a subclinical but 308 
chronic granulomatous inflammatory reaction initiated by the presence of the solid material 309 
following intramuscular injection in rats. Macrophages were shown to be recruited to the 310 
formulation depot site and phagocytosed large fractions of the injected depot which influenced 311 
the rate of drug release. Microscopy also revealed the presence of particle loaded 312 
macrophages, with the highest density located adjacent to the depot site. Particle loaded 313 
macrophages were also observed in the local draining lymph nodes [22]. This is of interest to 314 
ARV therapy as lymph nodes are major sanctuary sites for HIV and ongoing viral replication 315 
occurs in lymph nodes even when virus is undetectable in circulating blood [4,45]. 316 
Inflammatory processes are known to evoke lymphangiogenesis [46] which may contribute to 317 
enhanced lymphatic drainage from the depot. 318 
 319 
Further mechanistic studies were undertaken to investigate the effects of local macrophage 320 
infiltration and angiogenesis of the paliperidone palmitate prodrug depot. Paliperidone 321 
palmitate and paliperidone pharmacokinetics were assessed in rats following co-322 
administration of the inhibitors liposomal clodronate and sunitinib. Clodronate was used to 323 
inhibit the recruitment of macrophages towards the depot injection site and subsequent 324 
sequestration of the paliperidone palmitate depot. Sunitinib is a potent vascular endothelial 325 
growth factor (VEGF) receptor antagonist and tyrosine kinase inhibitor and was used to inhibit 326 
the local neovascularization of the paliperidone palmitate depot. Co-administration of 327 
clodronate decreased the rate at which the granulomatous reaction formed and macrophage 328 
infiltration into the paliperidone palmitate depot was slowed. This was shown to slow the rate 329 
of prodrug dissolution and conversion to the active form, demonstrated by the delayed 330 
paliperidone Tmax. Co-administration of sunitinib was shown to completely supress the 331 
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granulomatous reaction and inhibited the neovascularization of the paliperidone palmitate 332 
depot. Co-incubation with sunitinib was shown to delay paliperidone Tmax even further and 333 
reduced the Cmax from 89.0 mg/ml to 41.7 ng/ml. This suggests macrophage infiltration and 334 
subsequent phagocytosis of the paliperidone palmitate depot actively contributed to 335 
paliperidone plasma exposure by promoting prodrug dissolution and conversion from 336 
paliperidone palmitate to paliperidone. It also highlights the role of angiogenesis in enhancing 337 
the absorptive capacity around the depot site [24].   338 
 339 
The Cmax of the standard 300 mg MVC twice-daily oral regimen, at steady state, is 724.9 ng/ml 340 
with a Tmax and half-life of 3 h and 17 h, respectively [47]. The recommended minimum 341 
effective concentration for MVC therapy in HIV-1 infected adults and adolescents is between 342 
25 and 50 ng/ml depending on regimen followed [48,49]. Although Cavg is an established 343 
parameter relating to orally-dosed MVC efficacy [47], it is unlikely to be an appropriate 344 
comparison for LAIs particularly for PrEP applications. The results highlighted here suggest 345 
up to 10-days MVC exposure following intramuscular injection in rats. Clearly, for an LAI MVC 346 
preparation to be effective in humans a MVC plasma concentration above 25 ng/ml would 347 
need to be attained and sustained for at least 7-days. Inference of MVCSDNPVA/AOT’s long-acting 348 
potential in humans is difficult as interspecies pharmacokinetic scaling is complex [50]. 349 
Difference in muscle structure/density and metabolic processes between species are likely to 350 
influence pharmacokinetics. Additionally, differences in the ratio of formulation injection 351 
volume to muscle volume, between species, may have a direct effect on drug exposure (e.g. 352 
a more substantial ‘bust effect’ may be anticipated with a higher injection volume to muscle 353 
volume due to increased muscle stretching caused by the newly formed depot).   354 
  355 
Conclusions 356 
Suboptimal adherence to daily oral antiretroviral therapy continues to hinder the efficacy of 357 
HIV treatment and PrEP. The development of alternative drug administration strategies such 358 
as LAIs that provide bi-monthly, monthly or even less frequent administration intervals are 359 
emerging and may mitigate some shortfalls of current oral regimens [17]. Patients frequently 360 
experience “pill fatigue” following prolonged oral daily dosing, and attitude surveys have 361 
consistently demonstrated enthusiasm for LAI in both HIV therapy and PrEP [51,52]. In this 362 
exploratory study the MVCSDNPVA/AOT nanodispersion was developed and investigated for its 363 
potential as a LAI formulation. In vitro release rate assays revealed a reduced release rate 364 
constant for the nanodispersion compared to a conventional preparation of MVC. In vivo 365 
pharmacokinetic studies in rat demonstrated that MVC concentrations were detectable for up 366 
to 10-days, and cross-species differences in clearance may result in longer exposures in 367 
humans. Given the observed extended plasma exposure, further studies into MVC distribution 368 
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into biologically relevant tissues following intramuscular injection of the nanosuspension is 369 
warranted.  370 
  371 
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Figure 1. [3H]-MVC release rate across a size selective membrane for both a conventional 
[3H]-MVC preparation (<5% DMSO) or the nanodispersion MVCSDNPVA/AOT using either 
transport buffer (A) or simulated interstitial fluid (B) as both donor and acceptor media in a 
RED assay. The average release rate constant was calculated over 6 h for each preparation 
and the error bars give the standard deviations of the mean from three replicates.      
Figure 2. MVC exposure in adult male Wistar rats following a single intramuscular injection 
of [3H]-MVC (10 mg/Kg, 20 µCi mg [3H]-activity) in the biceps femoris either as a 
conventional preparation (<5% DMSO) or as the nanodispersion MVCSDNPVA/AOT. Data is 
expressed as plasma concentrations of [3H]-MVC over the initial 24 h (insert) or until plasma 
concentrations fell below the limits of detection (<2 ng ml). The fragmented lines give the 
standard deviations of the mean for three rats in each group.  
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Table 1. The pharmacokinetic parameters of MVC following intramuscular injection of [3H]-
MVC (10 mg Kg, 20 µCi mg [3H]-activity) in the biceps femoris either as a conventional 
preparation (<5% DMSO) or as the nanodispersion MVCSDNPVA/AOT. Parameters were 
calculated from the exposure curves outlined in Fig. 2.  
